Compare RSI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSI | ACAD |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.3B |
| IPO Year | 2020 | 2000 |
| Metric | RSI | ACAD |
|---|---|---|
| Price | $26.46 | $27.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 22 |
| Target Price | $28.20 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 933.33 | 69.12 |
| EPS | 0.19 | ★ 0.20 |
| Revenue | ★ $1,134,428,000.00 | $726,437,000.00 |
| Revenue This Year | $25.44 | $18.80 |
| Revenue Next Year | $14.27 | $11.70 |
| P/E Ratio | $140.63 | ★ $138.40 |
| Revenue Growth | 22.76 | ★ 40.45 |
| 52 Week Low | $15.51 | $19.69 |
| 52 Week High | $34.53 | $30.96 |
| Indicator | RSI | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 44.05 |
| Support Level | $26.00 | $25.00 |
| Resistance Level | $27.23 | $27.79 |
| Average True Range (ATR) | 1.03 | 0.75 |
| MACD | 0.25 | -0.37 |
| Stochastic Oscillator | 53.73 | 14.48 |
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.